Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Quigley

This article was originally published in The Tan Sheet

Executive Summary

Quigley: Purchase orders for Cold-Eeze zinc lozenges have reached $12.5 mil., the Doylestown, Penn. firm states Jan. 15. The manufacturer of the homeopathic cold product had announced a $3.5 mil. backlog in December, noting at the time its plans for expansion of its manufacturing facilities ("The Tan Sheet" Dec. 9, 1996, In Brief). With its increased manufacturing capacity, Quigley plans to produce around $1.5 mil. of Cold-Eeze per week. The company recently announced an anticipated $3.9 mil. in revenues and net earnings of $1.8 mil. for the first quarter ended Dec. 31. For the fiscal year ended Sept. 30, Quigley reported revenues of $1 mil. and a loss of $694,269, compared to $501,903 in revenues and a $152,556 loss in the previous fiscal year. Also, Quigley announced Jan. 17 that it has requested an investigation by the Securities & Exchange Commission into "attempts to discredit the company through fake press releases to the media and incorrect information posted on the Internet"...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts